Procedures & recovery · patient guide

Mitral TEER vs mitral valve repair: what the difference means

Mitral TEER (transcatheter edge-to-edge repair) and surgical mitral valve repair both target a leaking mitral valve, but they are not two versions of the same operation. TEER is a catheter-based procedure that clips the valve leaflets together without opening the chest. Surgical repair reshapes or reconstructs the valve during open-heart surgery. Which one fits a given patient is a decision for the treating heart team, based on valve anatomy, symptoms, heart function and other conditions.

Go to the practical guidance ↓
AI illustration: A golden balance scale with a medical instrument and a scalpel on each side, a stethoscope, clipboard, pen, and books on a wooden desk near a window with a potted plant.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

The core difference: a catheter clip versus an operation on the valve

The names are often used loosely, which causes confusion. Mitral valve repair is a surgical concept: the surgeon opens the chest, usually with cardiopulmonary bypass, and reconstructs the patient's own valve so it closes better. That may involve reshaping the annulus, shortening or transferring leaflet tissue, or repairing the structures that hold the leaflets in place. The valve is kept, not replaced.

Mitral TEER is a transcatheter procedure. A device is delivered through a catheter, typically via the femoral vein and across the atrial septum, and positioned so it clips the mitral leaflets together at the point of leakage. The aim is to reduce regurgitation without open surgery. It is a repair in the sense that the native valve is retained, but the technique, the access route and the recovery profile differ from surgical repair.

That distinction matters for a patient comparing options. TEER is not simply a smaller version of surgery, and surgical repair is not automatically the more complete treatment. Each has its own anatomical requirements, its own risks and its own evidence base, and the two are chosen for different clinical situations.

Related treatment reference

Why the heart team, not the patient, chooses between them

The decision is not a preference a patient can settle from a brochure. It depends on the mechanism of the leak, the shape and mobility of the leaflets, the size of the valve opening, the condition of the heart muscle, the presence of other heart disease and the patient's overall surgical risk. A heart team — typically cardiologists, imaging specialists and cardiac surgeons — reviews these together.

This is also where overseas patients can misjudge the question. A patient may arrive asking for TEER because it sounds less invasive, when the valve anatomy is better suited to surgery, or the reverse. The treating clinicians must assess the actual echocardiographic and clinical picture. A remote records review can help clarify what information is missing and what the hospital will need, but it does not establish final eligibility for either procedure.

For care in China, the relevant question is not which procedure is generally better. It is which procedure the receiving hospital's heart team would recommend for this patient's valve, and whether that team performs both routes so the comparison is genuine rather than limited by what one unit offers.

What the evidence says about each route

The evidence base is not symmetric. Surgical mitral valve repair is long established, particularly for degenerative mitral regurgitation, where durable repair is a recognised goal in suitable patients. TEER has been studied mainly in patients with primary (degenerative) mitral regurgitation who are at high surgical risk, and in secondary (functional) mitral regurgitation, where the leak results from ventricular disease rather than a primary leaflet problem.

In secondary mitral regurgitation, a landmark randomised trial compared TEER plus guideline-directed medical therapy with medical therapy alone and found a benefit for the combined endpoint in a selected population. That does not mean TEER is appropriate for every patient with functional regurgitation; selection criteria in the trial were specific, and the treating team must judge whether a given patient resembles that population.

For surgical repair, professional guidance from cardiac surgical and cardiology bodies addresses when repair is preferred over replacement and how to assess durability. These are clinical judgements, not rules a patient can apply alone. The practical point is that the two procedures have been tested in different populations, so a headline result for one cannot be transferred to the other.

Questions that actually move the decision forward

A useful consultation is built around the patient's own valve and heart, not general comparisons. The questions below are designed to surface the information the heart team needs and to make the reasoning visible.

Ask what the echocardiogram shows about the mechanism of the leak: is it primary leaflet disease or secondary to ventricular dysfunction? Ask whether the valve anatomy is suitable for TEER, and separately whether it is suitable for durable surgical repair. Ask what the team would recommend if the patient were younger or at lower surgical risk, and why that changes. Ask what the alternatives are if the preferred option is not feasible.

It is also reasonable to ask about the team's own experience with each route, how many of each procedure the unit performs, and what follow-up and imaging schedule they use. These are legitimate questions. The answers belong to the treating clinicians, and a coordinator cannot substitute for them.

Finally, ask what the plan would look like if the first-choice procedure turned out not to be possible after further imaging. A heart team that has considered the fallback is more informative than one that offers a single route.

  • Mechanism of the leak: primary leaflet problem or secondary to ventricular disease?
  • Is the valve suitable for TEER, for surgical repair, or for both?
  • What would the team recommend at lower surgical risk, and why?
  • What is the fallback if the preferred option proves unsuitable?
  • What imaging and follow-up does the team plan after either procedure?

Records to gather before asking a China hospital

The heart team's assessment depends on good imaging and a clear clinical history. A recent transthoracic echocardiogram report is central, and a transoesophageal echocardiogram is often needed to judge leaflet anatomy for TEER. Cardiac catheterisation or coronary angiography findings, if already done, help assess surgical risk. So do reports of heart function, rhythm, kidney function and lung disease, because these affect whether open surgery is safe.

Existing records should be sent as reports rather than summaries where possible, with the date of each study and the name of the imaging centre. If a test has not been done, that is a question for the treating team, not something to arrange independently before the hospital has reviewed the file. The hospital decides which additional tests it needs.

Patients should be clear about current medicines, especially anticoagulants and heart failure therapy, and about symptoms at rest and on exertion. These details shape the risk discussion. They do not, by themselves, determine which procedure is offered.

What this means for planning care in China

China has cardiac centres that perform both surgical mitral valve repair and transcatheter mitral procedures, but availability at a named hospital, and the composition of its heart team, must be confirmed for the individual case. A patient should not assume that because a procedure exists in the country it is offered at every centre or to every patient.

The practical route is to start with a short summary of the diagnosis, the echocardiogram findings and the main question, then let the hospital indicate what else it needs. An initial enquiry through ChinaSpecialistCare is free and does not commit the patient to a proxy consultation. A proxy consultation, where a doctor takes records to a specialist for a records-based opinion, is optional and is not a prerequisite for an appointment or an operation.

The hospital decides suitability, and no coordinator can promise acceptance or a particular outcome. What coordination can do is help match the case to a centre that performs the relevant procedures and prepare the records and questions so the clinical discussion is efficient.

If symptoms are worsening — increasing breathlessness, chest pain, fainting or signs of heart failure — local urgent assessment takes priority over planning travel. The next step for a stable patient is to send a brief summary and the key echocardiogram report, and ask the hospital which procedure its heart team would consider and what it needs to decide.

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Related treatment reference
  2. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guideli
  3. Heart valve replacement - NHS

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.